Is bisphenol A to blame for rise in male anomalies?
February 1st 2009A material used in plastic baby bottles and other products, which has been associated with such health risks as reproductive system abnormalities, prostate cancer, and obesity, could be banned this year, according to a professor at the University of Missouri, Columbia.
Urologists take a stand on Medicare Payment Advisory Commission payment proposal
February 1st 2009As the Obama administration and the 111th Congress move forward on health care reform, increased sentiment for finding ways to support primary care physicians appears to be building. Unfortunately, urologists and other specialists could be asked to ante up.
Popular selective serotonin reuptake inhibitor may reduce male fertility potential
February 1st 2009A recent prospective clinical trial found that the antidepressant paroxetine (Paxil) is associated with a five-fold increase in the risk of abnormal sperm DNA fragmentation as measured by terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) score.
Post-radical prostatectomy patients report satisfaction with injections
February 1st 2009Men who turn to intracavernosal injection (ICI) therapy following prostate surgery can generate a satisfactory rigid erection with as few as five practice (trial) injections, according to studies presented at the 2008 Fall Scientific Meeting of the Sexual Medicine Society of North America.
Studies shed light on erectile function in prostate cancer patients
February 1st 2009Erectile dysfunction is a fact of life for many men who receive treatment for prostate cancer, but methods of measuring post-treatment ED and erectile function recovery suffer from a lack of standardization, according to studies presented at the Sexual Medicine Society of North America 2008 Fall Scientific Meeting.
Poll results: Trial needed to compare prostatectomy, radiotherapy
January 29th 2009Results of an interactive feature on the web site of the New England Journal of Medicine suggest a need for a large, rigorous, decisive head-to-head clinical trial comparing radiotherapy and surgery for the treatment of prostate cancer.
Traditional factors may not explain why bladder cancer is deadlier for some
January 29th 2009Bladder cancer is more likely to be fatal for women and African-Americans, but University of Rochester researchers report that factors traditionally cited for these higher mortality rates are responsible for only about one-third of the difference between white men and women and up to two-thirds of the difference between African-Americans and their white counterparts.
Dr. Gleason, founder of prostate cancer grading system, dies
January 29th 2009Donald F. Gleason, MD, PhD, 88, died of a heart attack Dec. 28 in Edina, MN. Dr. Gleason, who retired from the University of Minnesota Medical School in 1986, was a central figure in the development of the Gleason grading system for prostate cancer tumors.
Pathology system used in prostate cancer granted patents
January 15th 2009The U.S. Patent and Trademark Office issued patent numbers to cover Aureon Laboratories, Inc.?s systems and methods for evaluating the occurrence of any medical condition in a patient where clinical, imaging, and molecular data are combined and appraised.
Underprivileged men more likely to receive advanced prostate cancer diagnoses
January 15th 2009Low-income men are more likely to present with advanced prostate cancers, most likely because they do not receive screening services shown to reduce the diagnosis of later-stage cancers, according to a study by UCLA researchers.
Researchers call for routine cystoscopy after hysterectomy
January 15th 2009Universal intraoperative cystoscopy following hysterectomy allows immediate repair of injuries to the ureter and bladder that would otherwise go undetected, according to a study published in Obstetrics & Gynecology (2009; 113:6-10).
Prostate cancer hormone therapy does not appear to increase cardiac deaths
January 15th 2009In a new study that appears to refute earlier research, Massachusetts General Hospital researchers have found that treating prostate cancer patients with gonadotropin-releasing hormone (GnRH) agonists does not appear to increase the risk of death from cardiovascular disease.